In addition, CDKN2A/B alterations were found in only 13.1% of recurring tumors in an analysis of 583 meningiomas [18] and in only 1 of 12 recurring atypical meningiomas (classified according to WHO 2016) by our group [19]. The gene discussed is CDKN2A; the disease is meningioma.